after administration of streptozotocin and treatment with the long-acting GLP-1R agonist taspoglutide administered once monthly vs. metformin in the drinking water for 12 wk. Taspoglutide did not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation was detected after taspoglutide or metformin. In contrast, hepatic triglyceride levels were significantly reduced in livers from taspoglutide-treated mice. Both peripheral and intracerebroventricular administration of exendin-4 rapidly decreased plasma triglyceride levels in fasted mice, and taspoglutide therapy in ApoE Ϫ/Ϫ mice modulated the expression of hepatic genes controlling fatty acid uptake and oxidation. We were unable to detect expression of the entire Glp1r coding sequence in macrophages isolated from ApoE Ϫ/Ϫ , C57BL/6, and IL10 Ϫ/Ϫ mice. Similarly, Glp1r mRNA transcripts were not detected in RNA from isolated murine hepatocytes. Using Western blotting and tissue extracts from Glp1r ϩ/ϩ and Glp1r Ϫ/Ϫ mice, and cells transfected with a tagged murine GLP-1R cDNA, we could not validate the sensitivity and specificity of three different GLP-1R antisera commonly used for the detection of GLP-1R protein. Taken T here are now multiple classes of antidiabetic medications used for the treatment of type 2 diabetes (1). All of these drugs were approved based on their ability to lower blood glucose; however, the mechanisms activated by distinct antidiabetic agents vary widely. Two of the relatively newer classes, glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, exert their glucose-lowering actions predominantly through activation of the GLP-1R (2) . Although classical islet actions of GLP-1 include stimulation of insulin and inhibition of glucagon secretion, GLP-1Rs are widely distributed on blood vessels and cardiomy-ocytes and exert direct effects in the cardiovascular system (3) . Activation of the GLP-1R also reduces blood pressure, decreases intestinal lipoprotein secretion, and attenuates inflammation, actions that might predict a favorable reduction in the development of atherosclerosis (4, 5) .
There are no completed long-term prospective clinical studies that address whether sustained GLP-1R activation modifies the risk of developing atherosclerosis, strokes, or heart attacks in diabetic individuals (6) . The actions of incretin-based therapies have been examined in shortterm studies of genetically modified rodents at high risk for development of atherosclerosis. Both GLP-1R agonists and DPP-4 inhibitors reduce lesion formation and monocyte or macrophage accumulation in the aorta of ApoE Ϫ/Ϫ mice (7-10); however, the majority of these experiments have been carried out in nondiabetic mice for short periods of time.
Although hyperglycemia and insulin resistance substantially accelerate the development of clinical and experimental atherosclerosis (11) , whether sustained activation of GLP-1R signaling might attenuate the development of atherosclerosis in the setting of insulin resistance, impairment of ␤-cell function, and hyperglycemia remains uncertain. We have now studied atherosclerosis progression in an established model of type 2 diabetes characterized by a combination of insulin resistance and ␤-cell dysfunction in high-fat fed mice administered the ␤-cell toxin streptozotocin (STZ) (12, 13) , followed by continuous treatment with the long-acting GLP-1R agonist taspoglutide for 12 wk. We also examined the expression of the GLP-1R in cell types important for control of ectopic lipid deposition, principally macrophages and hepatocytes. Our findings raise new questions about the mechanisms through which GLP-1R agonists attenuate the development of fatty liver and atherosclerosis in mice.
Materials and Methods

Animals
All experimental procedures on animals conformed to the guidelines and policies approved by the Mount Sinai Hospital Animal Care Committee. Mice were maintained on a 12-h light (0700 h), 12-h dark (1900 h) cycle in a specific pathogen-free environment and had ad libitum access to food and water, except where noted. Four-week-old male ApoE Ϫ/Ϫ mice from The Jackson Laboratory (Bar Harbor, ME) were started on a high-fat (45% kcal) diet (D12451; Research Diets, New Brunswick, NJ). Modest hyperglycemia was induced using STZ (an initial dose of 75 mg/kg followed by a second dose of 125 mg/kg 10 d later), and mice with glucose levels from 15-25 mM were then randomized to different groups and treated for 12 wk with a once-monthly sc 0.4-mg taspoglutide microtablet suspension, a sc placebo microtablet, or metformin (400 mg/kg⅐d) continuously provided in the drinking water plus a sc placebo microtablet, as described in Supplemental Fig. 1 (published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). The STZ dosing regimen was based on pilot experiments and chosen to produce modest hyperglycemia, but not complete ␤-cell destruction. Preliminary dose-response experiments in mice verified that this dose of taspoglutide produced continuously elevated circulating levels of immunoreactive taspoglutide and effective glucose control without marked weight loss; the dose of metformin was based on dose-ranging pilot studies in ApoE Ϫ/Ϫ mice and on previous studies (13, 14) . For isolation of tissues and cells for RNA analysis, C57BL/6, IL-10 Ϫ/Ϫ (The Jackson Laboratory), Gipr Ϫ/Ϫ , and Glp1r Ϫ/Ϫ mice (15) were maintained on regular animal chow.
Body composition
Total body fat and lean mass were measured using a mouse whole-body magnetic resonance analyzer (Echo Medical Systems, Houston, TX) after 5 and 10 wk of treatment as described (16) . Food intake was measured and stool samples collected 3 d before euthanasia using single cages without bedding and preweighed food. On the last day, food and stool weights were recorded.
Oral glucose tolerance tests (OGTTs)
OGTTs were carried out after a 6-h fast (0700-1300 h). Glucose (1.5 mg/g body weight) was administered orally through a gavage tube, and blood glucose levels were measured by the glucose oxidase method using the Contour glucometer (Bayer Healthcare, Toronto, Ontario, Canada). For plasma insulin determinations, blood samples (50 l) were drawn from the tail vein in a heparinized tube. Blood was mixed with 10% (vol/vol) TED (500,000 IU/ml Trasylol, 1.2 mg/ml EDTA, and 0.1 mM diprotin A) and plasma separated by centrifugation at 4 C and stored at Ϫ80 C until assayed using a mouse insulin ELISA (Alpco, Salem, NH).
Macrophage, adipocyte, and hepatocyte isolation
Cells and tissues were obtained from 10-to 14-wk-old male mice, with the exception of ApoE Ϫ/Ϫ mice (20 wk). To collect activated macrophages, mice were injected with 2 ml 4% thioglycolate 5 d before peritoneal extraction. Peritoneal cells were either immediately harvested for RNA, plated for 1 h in a six-well tissue culture plate, or subjected to fluorescence-activated cell sorting (FACS). For FACS purification, macrophages were identified as positive for both F4/80 (eBioscience, San Diego, CA, catalog item 12-4801) and CD11b (eBioscience, catalog item 17-0112). Adipose tissue macrophages were collected after collagenase digestion of adipose tissue, and FACS was used to isolate cells from the stromal vascular fraction, using F4/80 and CD11b as positive markers. Hepatocytes and the nonhepatocyte fraction (17) and adipocytes and the stromal vascular fraction were separated as described (18) .
RT-PCR analysis
Mouse Glp1r mRNA analysis was performed as described (19) . The mouse Glp1r transcript was amplified by PCR using primer pairs 5Ј-GTACCACGGTGTCCCTCTCA-3Ј and 5Ј-CCTGTGTCCTTCACCTTCCCTA-3Ј, resulting in generation of a PCR product encompassing the majority of the GLP-1R open reading frame and nucleotides within the 3Ј-untranslated and 3Ј-flanking region. After gel electrophoresis and transfer to membranes, blots were hybridized with a 32 P-labeled (5Ј-GGATGGGCTCCTCTCCTATC-3Ј) GLP-1R oligonucleotide. ␤-Actin RNA analysis by PCR was performed using primer pairs 5Ј-TGACATCCGTAAAGA-3Ј and 3Ј-CAGCTCAGTAA-CAGTCC-5Ј. For analysis of gene expression in liver (Supplemental Table 1 ), cDNA from whole liver was subjected to realtime PCR analysis using the TaqMan real-time PCR gene expression assay (Applied Biosystems, Foster City, CA), with Ppia used as the internal control gene. Glp1r cDNA was cloned from Glp1r Ϫ/Ϫ lung and intestine into a TA cloning vector, sequenced, and subcloned into pcDNA3.1/myc-His(Ϫ) (Invitrogen Canada, Burlington, Ontario, Canada) for transfection into BHK fibroblasts as described below.
Detection of GLP-1R protein by Western blotting
Whole tissue extracts from mouse lung and BHK cell lysates were prepared by homogenization in RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate in PBS) supplemented with protease inhibitor cocktail (Sigma-Aldrich, Oakville, Ontario, Canada). Thirty to forty micrograms of protein were resolved by SDS-PAGE and immunoblotted as described (20) . Immunoprecipitations were performed using the ImmunoCruz IP/WB Optima F System (Santa Cruz Biotechnology, Santa Cruz, CA), Protein A Plus Agarose (Thermo Scientific, Rockford, IL), or Sepharose-conjugated anti-Myc-Tag (9B11) mouse monoclonal antibody (Cell Signaling Technology, Beverly, MA). Immune complexes were resolved by SDS-PAGE and analyzed by immunoblotting. The following rabbit polyclonal antibodies to the GLP-1R were used: sc-66911 (Santa Cruz Biotechnology), LS-A1205 (LifeSpan Biosciences, Seattle, WA), and ab39072 (Abcam, Cambridge, MA). The rabbit polyclonal anti-His-Tag antibody was from Cell Signaling Technology, and the mouse monoclonal anti-c-myc (9E10) antibody was from Santa Cruz. Transient transfection of BHK cells with 1) the murine Glp1r ϩ/ϩ cDNA or 2) the Glp1r Ϫ/Ϫ lung cDNA (long form; see Fig. 7 ) cloned into pcDNA3.1/myc-His(Ϫ) or 3) the empty vector was done using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol.
Plasma triglycerides in response to peripheral or intracerebroventricular exendin-4
C57BL/6 male mice, 8 wk of age, were placed on a high-fat (45% kcal) diet for 4 wk, then fasted overnight. On the day of the experiments, a blood sample was collected via the tail vein, and mice were injected with exendin-4 or saline either ip or via a stereotaxic intracerebroventricular injection as described (21, 22) . Immediately after exendin-4 or vehicle administration, mice were injected iv with Triton WR1339 to block triglyceride clearance (0.5 mg/kg body weight, 15% solution prepared in saline). Blood samples were collected 1, 2, and 3 h after Triton WR1339 injection and centrifuged for 5 min at 6000 rpm, and plasma triglyceride levels were determined enzymatically (23) .
Lipid tolerance test
After 6 wk of treatment with placebo, metformin, or taspoglutide, ApoE Ϫ/Ϫ mice were fasted overnight (1900-0900 h), and a lipid tolerance test was carried out as described (23) .
Plasma cholesterol and adipokines
Blood (50 l) was withdrawn from fasted ApoE Ϫ/Ϫ mice (1900-0900 h), mixed with 10% (vol/vol) TED (500,000 IU/ml Trasylol, 1.2 mg/ml EDTA, and 0.1 mM diprotin A), and plasma was separated by centrifugation at 4 C and stored at Ϫ80 C. Plasma was assayed for cholesterol using an enzymatic colorimetric assay kit (Wako, Richmond, VA, catalog item 439-17501). The Milliplex MAP Mouse Serum Adipokine Kit (EMD Millipore, Billerica, MA, MADPK-71K) was used to measure plasma levels of leptin, IL-6, resistin, TNF-␣, and monocyte chemotactic protein-1.
Mean arterial pressure
Arterial pressure was measured from 1030-1530 h in trained awake ApoE Ϫ/Ϫ mice using an automated tail cuff system (BP-2000; Visitech Systems, Apex, NC) after 11 wk of treatment.
Histological analysis
The aortic root was isolated for quantification of atherosclerosis lesion size as described (24) . ImageScope software version 11.0.2.716 (Aperio, Vista, CA) was used to quantify plaque area and lipids. The 15th and 20th aortic sections were stained with MAC-2 primary antibody (Cedarlane Laboratories, Burlington, Ontario, Canada) and visualized with diaminobenzidine. The liver embedded in OCT was cut and stained with hematoxylin and eosin and Oil-Red O. Histological sections were scored for hepatic lobular inflammation, ballooning, apoptosis, Kupffer cells, fibrosis, and steatosis according to guidelines set by the Pathology Committee of the NASH (nonalcoholic steatohepatitis) Clinical Research Network (25) in a blinded manner by a trained pathologist (C.S.).
Statistics
Results are presented as mean Ϯ SE. Statistical analyses were done using repeated-measures ANOVA followed by Bonferroni's post hoc test. A P value Ͻ 0.05 was considered to be statistically significant. Sample size calculations were approximated using GraphPad StatMate version 2.00 software. The largest SD and a power of 80% were chosen to estimate the required sample size (n) per treatment group. The effect size was estimated from the mean difference observed between controls and taspoglutide-treated mice.
Results
Taspoglutide treatment of ApoE
The results of previous studies demonstrated that continuous GLP-1 or exendin-4 administration attenuated the development of atherosclerosis in normoglycemic ApoE Ϫ/Ϫ mice (7, 10) . Accordingly, we carried out experiments to assess the consequences of GLP-1R activation in hyperglycemic ApoE Ϫ/Ϫ mice employing the long-acting GLP-1R agonist taspoglutide (26) vs. the commonly used antidiabetic agent metformin, employed as a control for actions that might simply reflect improved glucoregulation (Supplemental Fig. 1 ). Taspoglutide significantly de-creased food intake and body weight ( Fig. 1, A and B ). There were no significant differences in percent fat mass (Fig. 1C ) or blood pressure (Supplemental Fig. 2A ); epididymal white adipose tissue was lower in taspoglutidetreated mice, but the difference was not significant (Fig.  1D ). Blood glucose levels remained elevated (ϳ15 mM) even 2 h after glucose loading during an OGTT in placeboand metformin-treated mice (Fig. 1E ). In contrast, taspoglutide-treated mice exhibited significantly improved oral glucose tolerance (Fig. 1E ) and an increased insulin to glucose ratio (Fig. 1F ). Hemoglobin A1c levels were lower in taspoglutide-treated mice, but the difference was not statistically significant (P ϭ 0.19) (Fig. 1G ). Plasma levels of IL-6 were significantly reduced in ApoE Ϫ/Ϫ mice treated with metformin or taspoglutide, leptin levels were unchanged, and plasma resistin was increased in taspoglutide-vs. metformin-treated mice ( Fig. 1 , H-J). No significant changes in lipid tolerance as assessed by changes in plasma triglycerides after olive oil loading, fasting plasma cholesterol or triglycerides, or fecal cholesterol were detected across treatment groups, however fecal triglycerides were higher in the taspoglutide-treated mice (Supplemental Fig. 2 ). Taspoglutide-treated ApoE Ϫ/Ϫ mice exhibited significantly increased plaque area in the aortic sinus compared with metformin-treated mice (Fig. 2 , A and F). Intraplaque lipid was significantly reduced in metformin-treated mice but unchanged after taspoglutide administration (Fig. 2B ). Total macrophage area was not different across treatment groups in the aortic sinus (Fig. 2C ) or in the aortic arch (Fig. 2 , D and G). Neither metformin nor taspoglutide significantly reduced plaque area in the abdominal aorta ( Fig. 2 , E and H). The failure of taspoglutide to reduce aortic plaque area in hyperglycemic ApoE Ϫ/Ϫ mice differs from results obtained with GLP-1R agonists in previous studies of ApoE Ϫ/Ϫ mice (7, 10) . Accordingly, we next examined the consequences of taspoglutide therapy on the liver, an organ that is also highly susceptible to ectopic lipid deposition and responsive to therapy with GLP-1R agonists in clinical and experimental models of diabetes (27) (28) (29) . Liv- ers from diabetic mice treated with taspoglutide weighed significantly less compared with livers from metformintreated mice (Fig. 3A) ; however, parameters of liver injury were similar in control vs. metformin-or taspoglutidetreated mice (Supplemental Fig. 3 ). Livers from mice treated with taspoglutide appeared healthier with no gross nodular enlargement and exhibited significantly reduced levels of triglycerides and cholesterol (Fig. 3, B-D) . Cholesterol and triglyceride levels in stools were not significantly different among the three groups (Supplemental Fig. 2, E and F) .
We next explored mechanisms through which GLP-1R agonists modify hepatic lipid accumulation. Because acute intracerebroventricular exendin-4 administration reduced hepatic triglyceride levels in mice under hyperinsulinemiceuglycemic clamp conditions (30), we assessed hepatic lipid secretion in high-fat-fed mice. Acute peripheral or intracerebroventricular administration of exendin-4 rapidly reduced plasma triglyceride levels in fasted mice after 4 wk of high-fat feeding, demonstrating that GLP-1R activation leads to reduction rather than stimulation of hepatocyte triglyceride secretion in the absence of hyperinsulinemia (Fig. 4, A and B) .
Analysis of gene expression profiles for mRNA transcripts encoding proteins involved in the regulation of cholesterol, free fatty acid, and triglyceride metabolism is shown in Fig. 5 and Supplemental Table 2 . Taspoglutide treatment significantly increased levels of mRNA transcripts for the transcription factor liver X receptor (Lxr) as well as multiple LXR target genes, Abca1, Abcg5, Abcg1, and Abcg8 (Fig. 5, A-E) , involved in cholesterol shuttling and clearance. The mRNA levels of Lrp were also increased after taspoglutide administration (Fig. 5F ). In addition, the expression of the scavenger receptor (Sr) mRNA, involved in cholesterol-rich high-density lipoprotein and low-density lipoprotein uptake by hepatocytes, was also up-regulated in taspoglutide-treated mice (Fig.  5G) . Taspoglutide also increased mRNA levels for hepatic lipase (Lipc), a key enzyme in the regulation of triglyceride storage and clearance (Fig. 5H) , as well as Cpt1a, a ratelimiting mitochondrial fatty acid carrier regulating the rate of free fatty acid ␤-oxidation (Fig. 5I) . Conversely, expression of Fabp1, Fabp2, and Fatp5, genes important for free fatty acid uptake and shuttling (Fig. 5 , J-L), and perilipin (Fig. 5M) , a marker of mature lipid droplets, was reduced in taspoglutide-treated livers. Taken together, these findings suggest that GLP-1R agonists induce a gene expression program favoring increased cholesterol, triglyceride, and fatty acid hepatic clearance and reducing the amount of free fatty acids taken up by hepatocytes.
Previous studies suggested that GLP-1R agonists control ectopic lipid deposition in part through direct activation of the native GLP-1R expressed on macrophages and hepatocytes (7, 31) . Surprisingly however, we were unable to detect expression of Glp1r mRNA transcripts from macrophages isolated under a variety of conditions from three different lines of mice (wild-type C57BL/6, ApoE Ϫ/Ϫ , and IL10 Ϫ/Ϫ );
however, Glp1r mRNA transcripts were readily detected in RNA from murine islets, lung, and heart (Fig. 6A) . Furthermore, although a weak signal corresponding to Glp1r mRNA transcripts was detected in RNA isolated from mouse liver, we did not detect a Glp1r mRNA transcript in RNA from isolated murine hepatocytes (Fig. 6A) . Because several groups have reported 
FIG. 3. Liver weights and lipid levels in diabetic ApoE Ϫ/Ϫ mice. Liver weights (panel A), triglycerides (panel B), cholesterol concentrations (panel C), and images of livers (panel D) after treatment of diabetic (D) ApoE
Ϫ/Ϫ mice with vehicle alone (PBO), metformin (Met), or taspoglutide (TASPO). BW, Body weight; HFD, high-fat diet. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. Comparison between groups was made by one-way or two way ANOVA.
detection of an immunoreactive GLP-1R protein in macrophages and liver cells, we assessed the sensitivity and specificity of three different commercially available GLP-1R antisera commonly used to detect immunoreactive GLP-1R protein by Western blotting and/or immunocytochemistry. Remarkably, we were unable to verify that these antisera detect the native GLP-1R protein in conventional Western blot analysis using lung extracts from Glp1r ϩ/ϩ and Glp1r Ϫ/Ϫ mice (Fig. 6B) , although the antisera did detect several immunoreactive bands ranging in size from approximately 54-65 kDa. To enhance the sensitivity of GLP-1R detection, protein extracts from mouse lung were first immunoprecipitated with one of two different GLP-1R antisera, after which immunoprecipitates were subjected to Western blot analysis with different GLP-1R antisera. Although multiple proteins ranging in size from approximately 54-96 kDa were detected (Fig. 6C) , the number and relative abundance of proteins detected was comparable using lung extracts from Glp1r ϩ/ϩ and Glp1r Ϫ/Ϫ mice.
The results of these experiments suggested that these GLP-1R antisera were unable to detect the endogenous immunoreactive GLP-1R in murine tissues using conditions traditionally employed for conventional Western blot analysis. Accordingly, we transfected a C-terminal myc-His epitope-tagged murine GLP-1R cDNA into fibroblasts and repeated the experiments using extracts from transfected cells. Western blot analysis of whole-cell extracts did not detect the authentic immunoreactive GLP-1R protein, because identical immunoreactive bands were detected in cells transfected with the mouse GLP-1R cDNA or the cDNA expression vector pcDNA3.1/mycHis alone (Fig. 6D) . In a further attempt to optimize the detection sensitivity of the GLP-1R antisera, we immunoprecipitated 500 g protein extract from cells expressing a tagged transfected GLP-1R cDNA using an anti-Myc epitope antisera, followed by Western blot analysis with each of the three different GLP-1R antisera. We observed a very faint immunoreactive GLP-1R protein with two of the three GLP-1R antisera corresponding to the predicted size of the control transfected GLP-1R protein detected using an anti-His tag antisera (Fig. 6E) . We next assessed whether immunoprecipitation with three different GLP-1R antisera followed by immunoblotting with an anti-c-myc antisera would detect a GLP-1R protein in BHK cells transfected with the mouse GLP-1R cDNA (Fig. 6F) . Nevertheless, we were unable to detect any difference between control and GLP-1R-transfected cell extracts in this more sensitive immunoprecipitation/Western blot analysis. In contrast, immunoprecipitation of the GLP-1R protein using an anti-His antibody, followed by immunoblotting with the anti-myc antisera, readily detected expression of the GLP-1R protein in transfected fibroblasts.
Analysis of the targeting vector used to generate
Glp1r
Ϫ/Ϫ mice (15), together with characterization of Glp1r mRNA transcripts from Glp1r Ϫ/Ϫ islets, reveals that disruption of the Glp1r gene results in an internal deletion within the Glp1r coding sequence (32) . We cloned Glp1r cDNAs from Glp1r Ϫ/Ϫ lung and intestine, and obtained two different sequences, designated the long and short Glp1r Ϫ/Ϫ cDNAs (Fig. 7, A and B ). Sequence analysis revealed internal deletion of exons 6 and 7 (long) or exons 6-12 (short), both of which encode a putative 186-amino-acid carboxyl-terminal truncated GLP-1R protein. Transfection of the cloned Glp1r Ϫ/Ϫ cDNA into BHK fibroblasts, followed by Western blot analysis using the anti-His antisera revealed a protein of less than 30 kDa, consistent with the Glp1r Ϫ/Ϫ cDNA sequence (Fig. 7, A and C). Hence, this much smaller GLP-1R-immunoreactive protein should be easily distinguished from the larger authentic GLP-1R when Glp1r Ϫ/Ϫ tissue extracts are used as controls in Western blot analyses.
Discussion
The available preclinical data demonstrate that GLP-1R agonists attenuate atherosclerosis progression (4). Continuous exendin-4 administration for 4 wk to young normoglycemic ApoE Ϫ/Ϫ mice fed standard rodent chow reduced macrophage adhesion to endothelial cells and aortic plaque and significantly decreased plaque area in the aortic sinus (7) . Similarly, continuous administration of native GLP-1(7-36)amide for 4 wk reduced macrophage accumulation and aortic lesion size in young nondiabetic ApoE Ϫ/Ϫ mice, through mechanisms sensitive to the GLP-1R antagonist exendin(9-39) (10). Comparable antiatherogenic actions have been observed after administration of DPP-4 inhibitors to ApoE Ϫ/Ϫ mice, findings attributable to antiinflammatory actions of GLP-1R signaling in macrophages and endothelial cells (8, 33) . In contrast, our findings in high-fat-fed STZ-treated ApoE Ϫ/Ϫ mice differ substantially from previous reports in that we failed to detect evidence for GLP-1R-dependent reduction of lesion size in the thoracic or abdominal aorta. The lack of antiatherogenic activity in our studies may reflect the longer duration of treatment, the dose of taspoglutide used, the older age of mice, or the greater degree of hyperglycemia obtained after the combination of highfat feeding and STZ. We intentionally selected doses of metformin and taspoglutide that produced glucoregulatory actions without producing substantial effects on food intake and body weight loss. It seems likely that treatment of mice with higher doses of these agents, leading to more profound weight loss, might enhance the antiatherogenic properties of antidiabetic agents. Nevertheless, our negative findings suggest that sustained GLP-1R activation, at levels sufficient to control blood glucose, does not universally lead to reduction of experimental atherosclerosis, and more work is clearly needed to understand the conditions and dose-response relationships required for coupling of GLP-1R activation to reduction of aortic plaque. An equally unexpected finding was the lack of effect of taspoglutide on macrophage accumulation in the thoracic or abdominal aorta in ApoE Ϫ/Ϫ mice. The inflammatory state and migratory capacity of macrophages may be influenced by ambient levels of glucose, insulin, and free fatty acids (5) , and changes in these parameters in our diabetic ApoE Ϫ/Ϫ mice may have contributed to the failure of GLP-1R agonists to reduce macrophage adhesion to the aortic plaque or endothelium (11) . Considerable evidence demonstrates that GLP-1R activation reduces lipid accumulation, attenuates endoplasmic reticulum stress, reduces macrophage migration, and decreases the expression of proinflammatory molecules in murine macrophages (7, 9, 10, (34) (35) (36) . Nevertheless, we were unable to detect expression of the full-length Glp1r mRNA in peritoneal or adipose tissue macrophages isolated under various conditions from mice of multiple different genetic backgrounds. The majority of published studies assessing Glp1r mRNA expression in various cells and tissues such as macrophages rely predominantly on real-time PCR, which is highly sensitive but less specific relative to the detection of full-length Glp1r mRNA transcripts using techniques such as regular PCR and primers that enable detection of the entire GLP-1R coding sequence. Hence, although GLP-1R activation may indirectly control macrophage activation or migration, our data raise uncertainty about the direct actions of GLP-1R agonists on murine macrophages. Characterization of several antisera commonly used to detect immunoreactive GLP-1R protein reveals that these antisera are not sufficiently sensitive to detect the native GLP-1R protein in cells or tissues using conditions routinely used for Western blot analysis. We selected lung extracts as a positive control for these experiments, because Glp1r expression has been reported to be relatively abundant in lung (Fig. 6 ) compared with other tissues (37) . Furthermore, we were similarly unable to detect the GLP-1R protein with three different antisera in cells transfected with the GLP-1R cDNA, conditions favoring robust expression of the GLP-1R that is normally expressed at much lower levels in endogenous cells and tissues. Our experiments reveal that each of these antisera detect a number of nonspecific bands (evident in extracts from Glp1r Ϫ/Ϫ mice and cells transfected with the control pcDNA3.1/myc-His plasmid alone) of similar molecular size to the predicted immunoreactive GLP-1R. These findings raise a note of caution about interpretation of data generated using these antisera to detect GLP-1R expression in cell and tissue extracts and reemphasize the importance of appropriate controls in the interpretation of data obtained using the antisera. The use of Glp1r Ϫ/Ϫ tissues as a control for assessing the sensitivity and specificity of GLP-1R antisera requires consideration of the possibility that under some circumstances, tissues from Glp1r Ϫ/Ϫ mice may express a smaller nonfunctional GLP-1R-immunoreactive protein that exhibits a molecular mass at least 20 kDa smaller than the authentic full-length GLP-1R protein (32 (27, (38) (39) (40) (41) (42) . Chronic GLP-1R activation reduces hepatic very-low-density lipoprotein production in highfat-fed mice (43) , and acute intracerebroventricular administration of GLP-1 during hyperinsulinemic-euglycemic clamp experiments rapidly reduced hepatic triglyceride content in high-fat-fed mice (30) . Nevertheless, we observed that acute exendin-4 administration via the intracerebroventricular or peripheral routes actually reduced triglyceride secretion into plasma of fasted mice, consistent with GLP-1R-dependent inhibition of hepatic lipid secretion. Our findings are in agreement with studies in high-fat-fed mice chronically infused with intracerebroventricular GLP-1 for 2 wk that also exhibited reduced plasma triglyceride levels under hyperinsulinemic-euglycemic conditions (44 (31, 38, 41, 45) . In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, (47) (48) (49) , and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17) . Our current PCR analysis using primers that span nearly the entire Glp1r coding region failed to detect Glp1r expression in isolated murine hepatocytes, whereas the faint transcript in RNA isolated from whole liver is consistent with a signal emanating from blood vessels, bile ducts, neurons, or infiltrating immune cells within the liver. Hence, the reduction in liver fat in mice treated with GLP-1R agonists is not explained by a direct effect of GLP-1R signaling in hepatocytes.
In summary, our results raise several questions surrounding GLP-1 action, atherosclerosis, and hepatic fat accumulation. Our findings fail to demonstrate attenuation of atherosclerosis in either the thoracic or abdominal aorta of diabetic ApoE Ϫ/Ϫ mice. Furthermore, we did not observe reduced macrophage accumulation in the aorta after sustained GLP-1R activation, and we were unable to detect Glp1r mRNA transcripts in macrophages or hepatocytes, despite previous reports localizing the GLP-1R to these two cell types. Importantly, our findings reveal substantial problems with the sensitivity and specificity of multiple GLP-1R antisera commonly used for the detection of the GLP-1R in various tissues. Taken together, our findings emphasize the importance of additional experimentation to identify mechanisms and conditions linking GLP-1R activation to the control of macrophage migration, hepatocyte lipid metabolism, and ectopic lipid deposition. 
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